Chembio Diagnostics to Report Third Quarter 2021 Financial Results on November 4, 2021
Chembio Diagnostics, Inc. (CEMI) will announce its third-quarter financial results on November 4, 2021, after market close. Following the release, a conference call will be held at 4:30 p.m. ET for investors to discuss the results. The call can be accessed via phone or online. Chembio specializes in point-of-care diagnostics for infectious diseases, including COVID-19, and has a global market presence. The company aims to leverage its innovative DPP technology for a variety of applications beyond infectious diseases.
- Chembio's DPP technology offers broad market applications beyond infectious diseases.
- The company's products are sold globally, offering a diverse revenue stream.
- None.
HAUPPAUGE, N.Y., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the third quarter of 2021 after the close of trading on Thursday, November 4, 2021.
The company’s management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time on November 4, 2021. Investors interested in listening to the conference call may do so by dialing 888-506-0062 from the US or 973-528-0011 from outside the US and providing Entry Code: 938540 or by accessing www.chembio.com/investors/calendar-of-events/. A replay of the call will be available by dialing 877-481-4010 from the US or 919-882-2331 from outside the US using passcode 43155 or by accessing www.chembio.com/investors/calendar-of-events/.
About Chembio Diagnostics
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.
Investor contact:
| Philip Taylor Gilmartin Group (415) 937-5406 investor@chembio.com |
FAQ
When will Chembio Diagnostics release its Q3 2021 financial results?
What time is Chembio's Q3 2021 conference call?
How can I access Chembio's Q3 2021 earnings call?
What is Chembio Diagnostics focused on?
